Roche's Elecsys pTau217 blood test, co-developed with Eli Lilly, received CE-mark approval in Europe on May 12, 2026. This is the second Alzheimer's blood test approved in Europe, following the earlier pTau181 test. pTau217 offers both rule-in and rule-out capabilities for Alzheimer's, unlike pTau181 which mainly rules out amyloid pathology. Validated for use in both primary and specialist care settings. Expected availability in CE-marked European markets starting July 2026. Has breakthrough device designation from the U.S. FDA. Sources:
- Get link
- X
- Other Apps